This site is intended for healthcare professionals

CHMP recommends Lynparza to treat metastatic castration-resistant prostate cancer with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations.- AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:16th Mar 2021
Published:22nd Sep 2020
Condition: Prostate Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

DNA Repair in Prostate Cancer

Find out how DNA repair gene alterations impact on prostate cancer clinical practice, guidelines on molecular testing, and strategies for testing DNA repair gene alterations.